Toshiba software debuts on SNM floor
Three software packages, each a work-in-progress, were highlights at the Toshiba America booth during the SNM meeting in Philadelphia. The company also released new versions of the e.soft software platform on which the t.cam gamma camera runs. Toshiba's
Three software packages, each a work-in-progress, were highlights at the Toshiba America booth during the SNM meeting in Philadelphia. The company also released new versions of the e.soft software platform on which the t.cam gamma camera runs. Toshiba's three WIPs-Sentinel Node Display, Automatic Registration Tool (ART), and Segmentation with Scatter and Photopeak window area for Attenuation Correction (SSPAC)-are designed for use on e.soft. Sentinel Node Display helps outline a patient's lymph nodes using scatter data. ART uses a segmentation method for automatically registering brain images, and SSPAC offers attenuation correction of cardiac SPECT without using a transmission source. Features now available on e.soft Version 3.5 and express version 2.0 allow improved display capabilities, including motion correction.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
